Design, Synthesis and Molecular Docking Studies of Novel Triazole-Chromene Conjugates as Antitubercular, Antioxidant and Antifungal Agents

A green and efficient protocol has been developed for the synthesis of novel 1,2,3-triazole-chromene conjugates (7 a-j) via ultrasound assisted and NaHCO3 catalyzed for the first time. Structures of all the new conjugates were deduced by various spectroscopic techniques. The newly synthesized triazole-chromene conjugates were evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis (MTB) H37Rv strain. The conjugates 7 f and 7 h were found to be most active with MIC value 12.5 mu g/mL. Furthermore, all the conjugates were screened for their antioxidant activity and are highly active (IC50=7.05-14 mu g/mL) than the reference drug BHT (16.47 mu g/mL). The triazole-chromene conjugates were also screened for their in vitro antifungal activity and some of the conjugates 7 a, 7 b, 7 d, 7 e, 7 f and 7 i were exhibited potent activity (MIC=6.25-25 mu g/mL) than the reference drug Miconazole. Docking studies showed significant binding affinity in the active site of Mycobacterium tuberculosis DprE1 enzyme.